Target intelligence / Profile preview

Kelch repeat and BTB domain-containing protein 13 (KBTBD13)

Target
KBTBD13
Molecular classification
Actin-binding protein, BTB domain-containing protein, Kelch-repeat protein, Accessory thin-filament protein, E3 ubiquitin ligase substrate adapter
01

Overview

Kelch repeat and BTB domain-containing protein 13 (KBTBD13) is a muscle-specific actin-binding protein. It is characterized by an N-terminal BTB (Broad complex, Tramtrack, and Bric-à-brac) domain and a C-terminal Kelch-repeat domain that forms a β-propeller structure. KBTBD13 plays a modulatory role in skeletal muscle contraction and relaxation by directly binding to sarcomeric actin filaments, impacting the kinetics and force of muscle contraction. Mutations in KBTBD13 cause Nemaline Myopathy type 6, a dominantly inherited congenital muscle disorder with slow muscle relaxation and structural thin-filament defects. Beyond its actin-binding function, KBTBD13 may act as a substrate adapter for a BTB-CUL3-RBX1 E3 ubiquitin ligase complex, potentially involved in selective protein degradation.

Other names
KBTBD13Kelch repeat and BTB domain-containing protein 13hCG_1645727NEM6Nemaline myopathy type 6HCG1645727kelch repeat and BTB (POZ) domain containing 13
02

Mechanism of action

Mutations in KBTBD13 alter actin filament properties—such as stiffness and periodicity—leading to impaired relaxation and decreased muscle contractile force. Putative role in ubiquitination through a BTB-CUL3-RBX1 E3 ligase complex (based on protein domain structure, not directly established).

03

Biological functions

Regulation of skeletal muscle relaxationModulation of muscle contraction kineticsStructural modulation of sarcomeric thin filaments (actin)Potential involvement in protein ubiquitination/degradation (via BTB-CUL3 E3 ligase complex)
04

Disease associations

Nemaline myopathy type 6 (NEM6)Childhood-onset nemaline myopathyPotential implication in other muscle weakness syndromes
05

Safety considerations

KBTBD13 mutations lead to impaired muscle relaxation, muscle weakness, and compromised contractility, which are clinically significant, especially in congenital myopathiesTherapeutic challenges include dominant-negative mutation effects and insufficient understanding of normal protein function
06

Interacting drugs

None documented.
07

Biomarkers

KBTBD13 mutation (e.g., R408C, I369M, K390N) status is a biomarker for Nemaline Myopathy type 6 diagnosis and patient selectionReduced relaxation kinetics or myofibril contractility in muscle biopsy (functional biomarker)

Beyond the preview

Go deeper on Kelch repeat and BTB domain-containing protein 13 (KBTBD13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelch repeat and BTB domain-containing protein 13 (KBTBD13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call